Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Clovis Oncology Inc (CLVS)

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 589,971
  • Shares Outstanding, K 88,319
  • Annual Sales, $ 143,010 K
  • Annual Income, $ -400,420 K
  • 60-Month Beta 2.10
  • Price/Sales 3.07
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CLVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 5
  • High Estimate -0.62
  • Low Estimate -0.88
  • Prior Year -1.81
  • Growth Rate Est. (year over year) +57.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.41 +51.47%
on 12/29/20
7.10 -5.92%
on 01/22/21
+1.66 (+33.07%)
since 12/22/20
3-Month
4.08 +63.73%
on 11/10/20
7.10 -5.92%
on 01/22/21
+1.05 (+18.76%)
since 10/22/20
52-Week
3.62 +84.53%
on 03/17/20
11.63 -42.56%
on 02/20/20
-2.46 (-26.91%)
since 01/22/20

Most Recent Stories

More News
Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2020. The financial information presented...

CLVS : 6.68 (+4.70%)
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug

Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.

AZN : 53.25 (+1.33%)
PFE : 36.55 (+0.19%)
GSK : 38.36 (+1.54%)
CLVS : 6.68 (+4.70%)
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for FAP-2286,...

CLVS : 6.68 (+4.70%)
Watch for Clovis Oncology to Potentially Rebound After Falling 2.23% Yesterday

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $4.82 to a high of $4.93. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $4.86...

CLVS : 6.68 (+4.70%)
Company News for Dec 22, 2020

Companies in the news are: LESL, RP, AJRD, CLVS

RP : 87.00 (unch)
CLVS : 6.68 (+4.70%)
AJRD : 52.51 (-0.47%)
LESL : 28.28 (-0.95%)
Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint

Clovis' (CLVS) Rubraca achieves significant improvement in progression free survival compared to chemotherapy in late-stage confirmatory study for BRCA-mutated ovarian cancer indication.

MRK : 80.98 (-0.25%)
GSK : 38.36 (+1.54%)
BMY : 64.56 (+0.59%)
CLVS : 6.68 (+4.70%)
Thinking about buying stock in Agios Pharmaceuticals, Clovis Oncology, Aqua Metals, Cocrystal Pharma, or Luminar Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGIO, CLVS, AQMS, COCP, and LAZR.

AGIO : 47.47 (-0.59%)
CLVS : 6.68 (+4.70%)
COCP : 2.11 (-4.52%)
LAZR : 34.00 (+3.50%)
AQMS : 4.79 (+3.68%)
Clovis Oncology's Rubraca(R) (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed progression-free...

CLVS : 6.68 (+4.70%)
Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

CLVS : 6.68 (+4.70%)
Alucio™ Adds Clovis Oncology to its Growing Roster of Life Science Customers

, /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced that Clovis Oncology has selected Alucio's Beacon as its scientific...

CLVS : 6.68 (+4.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

3rd Resistance Point 8.11
2nd Resistance Point 7.61
1st Resistance Point 7.14
Last Price 6.68
1st Support Level 6.17
2nd Support Level 5.67
3rd Support Level 5.20

See More

52-Week High 11.63
Fibonacci 61.8% 8.57
Fibonacci 50% 7.63
Fibonacci 38.2% 6.68
Last Price 6.68
52-Week Low 3.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar